Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes

Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes.
A young drug, the in the first place in its class, gives added blood sugar switch to people with type 2 diabetes who are already taking the glucose-lowering medication metformin. The unexplored agent, dapagliflozin, which also helped patients lose weight, is novel in that it does not work promptly on the body's insulin mechanisms, according to a study appearing in the June 26 issue of The Lancet and slated for image at the annual meeting of the American Diabetes Association (ADA) in Orlando proextenderdeluxe.com. "It will possibly be used as an add-on therapy," said study lead author Clifford Bailey, a chemical pathologist and professor of clinical art at Aston University in Birmingham, UK "If you don't degree get to target with the first therapy tried, this approach would offer you an opportunity expectedly to maintain improved control".

Bailey, who could not predict if or when the drug might get final approval from drug regulatory authorities, also trenchant out that dapagliflozin is flexible, meaning it can be used with various other treatments and at more or less any stage in the disease. "It's a company add-on," agreed Dr Stanley Mirsky, associate clinical professor of metabolic diseases at Mount Sinai Medical Center in New York City surgery. "is it a ponder drug? no. It may leeway a small role".

The study was funded by Bristol-Myers Squibb and AstraZeneca, which are developing dapagliflozin together. Dapagliflozin guts by stimulating the kidneys to eliminate more glucose from the body via urine. In this analyse of 534 adult patients with type 2 diabetes who were already taking metformin, the highest prescribe of dapagliflozin (10 milligrams daily) was associated with a 0,84 percent dwindling in HbA1c levels.

HbA1c is a measure of blood sugar control over time. Participants taking 5 mg of the downer saw a 0,70 percent decrease in HbA1c levels, while those taking 2.5 mg had a 0,67 percent decrease. In the placebo group, the decrement in HbA1c was 0,3 percent, the bone up found.

Weight loss was also greater in volunteers taking the study drug: 2,2 kilograms (4,8 pounds) in the 2,5 mg group; 3 kilograms (6,6 pounds) in the 5 mg group; and 2,9 kilograms (6,4 pounds) in the 10 mg group. Those in the placebo unit hopeless 0,9 kilograms, or almost 2 pounds. Much, though not all, of this diminution was likely to be tap water weight, the authors stated.

There were more genital infections seen among those taking dapagliflozin, the team noted. "One of the complications of the upper is an increase in urinary tract infections or yeast infections because you have high glucose levels in the urine," said Dr Jacob Warman, primary of endocrinology at The Brooklyn Hospital Center in New York City. "That's a very sufficient culture medium for yeast, so the endocrinologists aren't too contented about that".

On the other hand this drug appears to work without some of the kidney, liver and muscle complications of other drugs so "it would be extraordinary as an add-on to usual medications". A second study, also simultaneously being presented at the ADA engagement and published in The Lancet, found that adding inhaled insulin before each luncheon and long-acting insulin glargine before going to bed worked just as well as taking conventional therapy.

The routine therapy consisted of taking biaspart insulin twice a day. This is a combination of short-acting insulin and intermediate-acting insulin. The renewed regimen involved less weight gain, fewer episodes of proletariat blood sugar and was more convenient, according to the study, which was funded by MannKind, the maker of Technosphere, the inhaled insulin featured in the trial.

A third think over found that once-weekly injections of the drug Byetta (exenatide) worked better at controlling blood sugar levels than long-acting insulin. The business thus far has been to give Byetta twice a day. This study, funded by Amylin Pharmaceueticals and Eli Lilly, looked at a unknown formulation of the drug noflam.top. Patients who got the once-a-week materialize also lost an average of 2,6 kilograms (5,7 pounds), the go into found.